Holen Sie sich die Stockscreener-App
2.07
2.48%
0.05
Handel nachbörslich:
2.05
-0.02
-0.97%
Schlusskurs vom Vortag:
$2.02
Offen:
$2.1
24-Stunden-Volumen:
901.31K
Relative Volume:
1.71
Marktkapitalisierung:
$74.41M
Einnahmen:
$210.70K
Nettoeinkommen (Verlust:
$-21.37M
KGV:
-1.8818
EPS:
-1.1
Netto-Cashflow:
$-21.10M
1W Leistung:
+13.74%
1M Leistung:
+18.29%
6M Leistung:
+31.01%
1J Leistung:
+4.55%
1-Tages-Spanne:
$2.00
$2.20
1-Wochen-Bereich:
$1.80
$2.40
52-Wochen-Spanne:
$1.41
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Firmenname
Gain Therapeutics Inc
Sektor
Branche
Telefon
(301) 500-1556
Adresse
4800 HAMPDEN LANE, BETHESDA
Vergleichen Sie GANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.07 | 72.62M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-08-14 | Fortgesetzt | Oppenheimer | Outperform |
| 2021-04-12 | Eingeleitet | BTIG Research | Buy |
| 2021-04-12 | Eingeleitet | Oppenheimer | Outperform |
Gain Therapeutics Inc Aktie (GANX) Neueste Nachrichten
Gain Therapeutics Supports Reliable Data Management In Labs - kalkinemedia.com
Gain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim Group - Defense World
Is Gain Therapeutics Inc a good long term investmentVolume Spike Alerts & Small Budget Big Profits - earlytimes.in
Maxim Group Maintains Gain Therapeutics (GANX) Buy Recommendation - Nasdaq
Maxim Group Raises Price Target for Gain Therapeutics (GANX) to - GuruFocus
Gain Therapeutics reports preliminary Phase 1b data for Parkinson’s drug GT-02287 - Investing.com
Stock Traders Buy High Volume of Gain Therapeutics Call Options (NASDAQ:GANX) - MarketBeat
Gain Therapeutics reports positive early data from Parkinson’s trial - Investing.com
Gain Therapeutics reports positive early data from Parkinson’s trial By Investing.com - Investing.com Australia
Gain Therapeutics Reports Positive Interim Data from Phase 1b Study of GT-02287 in Parkinson’s Disease - Quiver Quantitative
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders® - Stock Titan
What to do if you’re stuck in Gain Therapeutics Inc.Breakout Watch & Daily Stock Trend Watchlist - newser.com
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 61.6% in September - MarketBeat
Detecting price anomalies in Gain Therapeutics Inc. with AITrade Analysis Report & Verified Stock Trade Ideas - newser.com
Does Gain Therapeutics Inc. stock trade at a discount to peers2025 Breakouts & Breakdowns & Community Shared Stock Ideas - newser.com
Is it time to cut losses on Gain Therapeutics Inc.July 2025 Pullbacks & AI Optimized Trading Strategy Guides - newser.com
Gain Therapeutics (NASDAQ:GANX) versus Karyopharm Therapeutics (NASDAQ:KPTI) Head-To-Head Review - Defense World
What moving averages say about Gain Therapeutics Inc.July 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Will Gain Therapeutics Inc. stock benefit from sector rotation2025 Technical Overview & Smart Investment Allocation Tips - newser.com
Applying Wyckoff theory to Gain Therapeutics Inc. stockWall Street Watch & Free Community Supported Trade Ideas - newser.com
Is Gain Therapeutics Inc. stock cheap at current valuation2025 Breakouts & Breakdowns & Risk Controlled Stock Alerts - newser.com
Analyzing drawdowns of Gain Therapeutics Inc. with statistical tools2025 Major Catalysts & Capital Efficiency Focused Strategies - newser.com
Can technical indicators confirm Gain Therapeutics Inc.’s reversal2025 Trading Recap & Reliable Volume Spike Trade Alerts - newser.com
What drives Gain Therapeutics Inc stock priceRisk Management Strategies & Investment Timing Techniques - earlytimes.in
What analysts say about Gain Therapeutics Inc stockEarnings Surprise Analysis & Superior Portfolio Growth - earlytimes.in
How to escape a deep drawdown in Gain Therapeutics Inc.Market Rally & Weekly Breakout Opportunity Watchlist - newser.com
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You - simplywall.st
Custom strategy builders for tracking Gain Therapeutics Inc.Gap Up & Free Reliable Trade Execution Plans - newser.com
What MACD signals say about Gain Therapeutics Inc.July 2025 Gainers & Community Supported Trade Ideas - newser.com
Finanzdaten der Gain Therapeutics Inc-Aktie (GANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.05%
4.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):